Form 4: Edwards Lifesciences Director Valeriani Receives Stock Grant

Nicholas J. Valeriani, a director at Edwards Lifesciences Corp, acquired 5,564 shares of common stock through a restricted stock unit grant.

Summary

• On May 9, 2025, Nicholas J. Valeriani, a director of Edwards Lifesciences Corp, received a grant of 5,564 restricted stock units.
• These restricted stock units were granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.
• The units will vest 100% after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
• Following the transaction, Valeriani directly owns 79,296 shares of Edwards Lifesciences common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine stock grant to a director, which is generally viewed as a neutral to slightly positive event as it aligns interests with shareholders.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The restricted stock units will vest 100% after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

Industry Context

Stock grants to directors are a common practice in publicly traded companies to incentivize and align their interests with shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock grants, are typical in the medical device industry to attract and retain qualified board members.
• Companies like Medtronic and Abbott also utilize stock-based compensation for their directors.

Stakeholder Impact

• The stock grant aligns the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, Stock Grant, Restricted Stock Units, Edwards Lifesciences, Valeriani